No black box warning on record for Augtyro

As of the latest FDA labeling reviewed, Augtyro (REPOTRECTINIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Augtyro medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Central Nervous System (CNS) Effects: Can cause CNS adverse reactions including dizziness, ataxia, and cognitive impairment. Withhold and then resume at same or reduced dose upon improvement, or permanently discontinue AUGTYRO based on severity. ( 5.1 ) • Interstitial Lung Disease (ILD)/Pneumonitis: Monitor patients for new or worsening pulmonary symptoms indicative of

No black box warning on record for Augtyro

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Central Nervous System (CNS) Effects: Can cause CNS adverse reactions including dizziness, ataxia, and cognitive impairment. Withhold and then resume at same or reduced dose upon improvement, or permanently discontinue AUGTYRO based on severity. ( 5.1 ) • Interstitial Lung Disease (ILD)/Pneumonitis: Monitor patients for new or worsening pulmonary symptoms indicative of

Augtyro Black Box Warning

No black box warning on record for Augtyro

Other warnings & precautions

Augtyro Black Box Warning

No black box warning on record for Augtyro

Other warnings & precautions